Get the Stockscreener App
11.55
2.30%
0.26
Pre-market:
11.55
Candel Therapeutics Inc stock is traded at $11.55, with a volume of 879.95K.
It is up +2.30% in the last 24 hours and down -10.19% over the past month.
Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
See More
Previous Close:
$11.29
Open:
$11.22
24h Volume:
879.95K
Relative Volume:
0.64
Market Cap:
$883.79M
Revenue:
$31,000
Net Income/Loss:
$-54.42M
P/E Ratio:
-11.81
EPS:
-0.9778
Net Cash Flow:
$-48.99M
1W Performance:
+1.85%
1M Performance:
-10.19%
6M Performance:
+140.12%
1Y Performance:
+112.71%
1-Day Range:
$10.85
$11.59
1-Week Range:
$10.78
$12.01
52-Week Range:
$4.35
$14.00
Candel Therapeutics Inc Stock (CADL) Company Profile
Name
Candel Therapeutics Inc
Sector
Industry
Phone
617-916-5445
Address
117 KENDRICK STREET, NEEDHAM
Compare CADL vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CADL
Candel Therapeutics Inc
|
11.55 | 883.79M | 31,000 | -54.42M | -48.99M | -0.9778 |
VRTX
Vertex Pharmaceuticals Inc
|
522.38 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
796.02 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
194.82 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
962.22 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
199.86 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Candel Therapeutics Inc Stock (CADL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-20-26 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-28-25 | Initiated | Stephens | Overweight |
| Sep-03-25 | Downgrade | BofA Securities | Buy → Neutral |
| Jun-30-25 | Resumed | H.C. Wainwright | Buy |
| Feb-20-25 | Initiated | Citigroup | Buy |
| Feb-19-25 | Initiated | Canaccord Genuity | Buy |
| Feb-07-25 | Initiated | BofA Securities | Buy |
| Dec-02-22 | Initiated | H.C. Wainwright | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Aug-23-21 | Initiated | Credit Suisse | Outperform |
| Aug-23-21 | Initiated | Jefferies | Buy |
| Aug-23-21 | Initiated | UBS | Buy |
View All
Candel Therapeutics Inc Stock (CADL) Latest News
This Small-Cap Biotech Is Having Its Best Week In A Month – Here’s What’s Driving It - Stocktwits
Candel Therapeutics upgraded to Strong Buy afte... - Pluang
Candel Therapeutics: Strong Buy On Aglatimagene Prostate Cancer BLA Filing In Q4 (CADL) - Seeking Alpha
H.C. Wainwright Remains a Buy on Candel Therapeutics (CADL) - The Globe and Mail
Candel Therapeutics stock jumps on BofA upgrade to buy - Investing.com
H.C. Wainwright Maintains Candel Therapeutics(CADL.US) With Buy Rating, Maintains Target Price $23 - Moomoo
Candel Therapeutics stock jumps on BofA upgrade to buy By Investing.com - Investing.com South Africa
BofA upgrades Candel Therapeutics stock rating on prostate cancer progress - Investing.com
Why is Candel Therapeutics stock surging today? By Investing.com - Investing.com Canada
BofA Upgrades Candel Therapeutics to Buy From Neutral, Price Target is $18 - marketscreener.com
Why CADL Stock Plunged Nearly 15% In After-Hours Trading Today - Stocktwits
Candel Therapeutics Inc (NASDAQ:CADL) Share Price | RNS News, Quotes, & Charts | CADL | - Proactive financial news
Candel Therapeutics at H.C. Wainwright conference: prostate cancer push By Investing.com - Investing.com India
CADL Slides As Form 144 Filing Flags Insider Selling Risk - timothysykes.com
CADL Stock On Track For Best Day In Nearly 16 Months — What’s Driving The Rally? - Stocktwits
CADL Stock Edges Up After Hours On Strong Extended Prostate Cancer Data - Stocktwits
CADL Slides As Candel Therapeutics Posts Wider Q2 Loss - StocksToTrade
Candel Therapeutics CEO Tak sells $3.16m in CADL stock By Investing.com - Investing.com Australia
Candel Therapeutics CEO Tak sells $3.16m in CADL stock - Investing.com
Candel Therapeutics (NASDAQ: CADL) CEO sells 280K shares under preset plan - Stock Titan
Candel Therapeutics (NASDAQ: CADL) investor plans $3.4M Rule 144 stock sale from equity awards - Stock Titan
Candel Therapeutics at Cantor global healthcare conference: prostate cancer push - Investing.com India
Candel (CADL) gives director options with 36-month vesting - Stock Titan
Candel Therapeutics, Inc. Announces Appointment of Martine Zimmermann to Board of Directors, Effective September 8, 2026 - marketscreener.com
Candel Therapeutics Adds Regulatory Veteran to Board Ahead of Q4 2026 BLA Submission - Minichart
Candel Therapeutics Adds Martine Zimmermann to Board Ahead of Planned BLA Filing - citybiz
Candel Therapeutics appoints Martine Zimmermann to board By Investing.com - Investing.com Canada
Candel Therapeutics appoints Martine Zimmermann to board - investing.com
Candel Therapeutics Appoints Martine Zimmermann, PharmD, to its Board of Directors - manilatimes.net
CADL 8-K FilingsCandel Therapeutics, Inc. SEC 8-K - Stock Titan
A drug-development expert with 30 years’ experience joins Candel’s board - Stock Titan
CADL Q2 2026 Earnings: EPS of -$0.52 Misses Consensus by 115.41% as Shares Decline 3.41%Quarterly Financial Update - careplusvn.com
BB: BlackBerry Ltd Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Candel Therapeutics Reported Better-Than-Feared Q1 Loss – But All Eyes Turn To This Pivotal Event Tomorrow - Stocktwits
(CADL) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Candel Therapeutics Stock Price Forecast. Should You Buy CADL? - StockInvest.us
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - manilatimes.net
Biotech Stocks At 52-Week HighsNEO, BLSM, RVMD, ORMP, CADL - RTTNews
Candel Therapeutics stock hits 52-week high at $13.96 By Investing.com - Investing.com South Africa
Candel Therapeutics stock hits 52-week high at $13.96 - investing.com
Oncolytic Virus Cancer Therapy Market Expected to Expand Rapidly During the Forecast Period (2026-2036) Amid Rising Investments in Next-Generation Cancer Treatments| DelveInsight - PR Newswire UK
Candel Therapeutics to Present at September Investor Conferences - manilatimes.net
Candel (CADL) Results Versus Estimates: EPS Comes in Above Forecast for the Current Session; Stock Move: The Share Price Adds 6.32% in the Latest ReadingHealthcare Earnings Report - careplusvn.com
Candel Therapeutics (CADL) Is Up 5.4% After Steep Q2 Loss Widening Has The Bull Case Changed? - Yahoo Finance
Analysts Issue Forecasts for CADL FY2026 Earnings - MarketBeat
Candel Therapeutics, Inc. (CADL) Stock Price, News, Quote & History - Yahoo Finance
Candel Therapeutics (CADL) Faces Bigger Losses As Its Valuation Still Looks Pricey - Yahoo Finance
Candel Therapeutics (CADL) Is Up 26.4% After Swinging Back to Losses in Q2 2026 – Has The Bull Case Changed? - simplywall.st
Candel Therapeutics Inc Stock (CADL) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
1.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):